Celcuity Inc. appointed Charles (Chip) R. Romp as a new independent director to its Board of Directors, effective February 11, 2026, increasing the Board size from seven to eight members. Mr. Romp brings over 25 years of pharmaceutical industry experience, including leadership roles at Secura Bio, Seagen, and Genentech, which is expected to provide valuable commercial oncology expertise as the company advances its lead candidate gedatolisib.
Key takeaways
Charles (Chip) R. Romp appointed as new independent director to Celcuity's Board of Directors, effective February 11, 2026.
Board size increased from seven to eight members with Mr. Romp's appointment.
Mr. Romp will receive annual compensation of $50,000 cash retainer and $100,000 equity award under the non-employee director compensation program.
Mr. Romp granted 215 shares of restricted stock upon appointment, vesting upon the earlier of the 2026 Annual Meeting or April 30, 2026.
Mr. Romp brings over 25 years of pharmaceutical industry experience, including CEO role at Secura Bio and executive positions at Seagen and Genentech.
Company's lead therapeutic candidate is gedatolisib, currently in Phase 3 trials for HR+/HER2- advanced breast cancer.